We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VXA-CoV2-1

News List

Vaxart’s Covid-19 vaccine shows cross-coronavirus activity in trial pharmaceutical-technology
May 06, 2021
Vaxart has reported the latest data from the Phase I trial of its first Covid-19 oral vaccine construct, VXA-CoV2-1, which showed broad cross-reactivity against other coronaviruses.
Vaxart’s oral vaccine candidate triggers immune response in Covid-19 trial pharmaceutical-technology
February 05, 2021
Vaxart has reported preliminary data from its Phase I study that showed its oral Covid-19 tablet vaccine candidate, VXA-CoV2-1, triggered multiple immune responses against SARS-CoV-2 antigens.
Vaxart Oral COVID-19 Vax Tablet Shows Promise contractpharma
February 04, 2021
Phase I study reached primary and secondary endpoints of safety and immunogenicity.
First patient dosed in COVID-19 vaccine tablet clinical trial europeanpharmaceuticalreview
October 16, 2020
A Phase I clinical trial to test VXA-CoV2-1, an oral tablet COVID-19 vaccine candidate, has been initiated with the first patient dosed.